Short answer
Penumbra Inc (PEN) filed its Q2 2018 10-Q quarterly report on Aug 7, 2018 for the quarter ended Jun 30, 2018.
Penumbra Inc Q2 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $109.6M, up 36.0% YoY from $80.6M
- Operating margin 8.5% vs negative 1.6% YoY, gross margin 65.9% vs 63.2%
- Best segment Peripheral Vascular, revenue $35.4M, up 45.3%; Neuro revenue $74.2M, up 32.0%
- Cash $59.7M vs $50.6M at December 31, 2017; operating cash flow $10.8M for six months
- Near-term headwinds: operating expenses expected to increase, clinical-trial costs and quarterly revenue variability展
Risk Factors
- No material changes or newly identified risks since the December 31, 2017 Form 10-K
- Carried-forward risks remain governed by the February 27, 2018 annual filing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Penumbra Inc quarterly reports
- Q3 2019 10-QFiled Nov 7, 2019
- Q2 2019 10-QFiled Aug 6, 2019
- Q1 2019 10-QFiled May 7, 2019
- Q3 2018 10-QFiled Nov 5, 2018
- Q1 2018 10-QFiled May 8, 2018
- Q3 2017 10-QFiled Nov 7, 2017
- Q2 2017 10-QFiled Aug 8, 2017
- Q1 2017 10-QFiled May 9, 2017
- Q3 2016 10-QFiled Nov 3, 2016
- Q2 2016 10-QFiled Aug 9, 2016
- Q1 2016 10-QFiled May 9, 2016
- Q3 2015 10-QFiled Nov 12, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.